ARCHIVES

President’s Budget Request for FDA Omits Funding for Critical Path.

This article is from The Cancer Letter archive.

Vol. 34 No. 05 | February 8, 2008

Download PDF Visit The Full Archive

Related Articles

ODAC Supports Approval For Taxotere In Breast Cancer, Hycamtin In Lung Cancer

June 5, 1998

Cancer Documentary Provides Argument for Increased Funding

May 23, 1986

Research Policy: NIH Trials Don’t Enroll Enough Women to Allow Analysis, GAO Says in Report

May 12, 2000

In Brief: FDA commissioner Kessler To Resign, Says His Goals Were Accomplished

November 29, 1996

FDA Gives Accelerated Approval To Tykerb For Metastatic Breast Cancer

February 5, 2010

NCI To Offer Expanded Access To Oxaliplatin

May 31, 2002